Navigation Links
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Date:3/9/2010

"Morbidities and organ loss due to CMV have become a significant medical issue as the frequency of organ transplantation has increased and new immunosuppressive regimes have been introduced," said George Painter, Ph.D., President and Chief Executive Officer.  "CMX001 has demonstrated broad-spectrum activity in preclinical tests against double-stranded DNA viruses - including CMV - and has been well-tolerated to date among volunteers and patients.  We believe that with this combination of potent antiviral activity and tolerability, CMX001 will prove to be a powerful new treatment option for the transplant population and their physicians."

The Phase 2 clinical study is being conducted at approximately 25 leading academic and medical research centers in the United States.  Enrollment in the study is under way and will include approximately 120 patients.  Study participants will receive CMX001 once weekly following stem cell engraftment through post-transplant week 13, and will be monitored for CMV disease and viremia.  Participants will also be monitored for other dsDNA viruses susceptible to CMX001, including adenovirus, BK virus, and Epstein Barr virus.  Safety assessments will be conducted throughout the study.  

About CMX001


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
2. Chimerix to Present at Two Upcoming Investor Conferences
3. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
4. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
5. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
6. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
10. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
11. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Net Medical Xpress Solutions, Inc., (OTC ... today the company has signed a letter of intent ... in Huntsville, AL . MedTel Solutions ... staffing and recruitment of telemedicine physicians. Consideration for the ... agreement, which is expected by June 30, 2013. ...
(Date:5/23/2013)... , May 23, 2013  CAS Medical Systems, Inc. (NASDAQ: ... for non-invasive patient monitoring, today announced that Thomas ... present at the 2 nd Annual Marcum MicroCap Conference ... in New York City . ... in the Estate 10 room and will be available via ...
(Date:5/23/2013)...  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) ... development and commercialization of novel bile acid therapeutics to ... today announced that Mark Pruzanski , ... the Deutsche Bank Securities 38th Annual Health Care Conference ... 29, 2013 at 4:10 p.m. ET. About ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2
... April 29 Today is an exciting day for ... ones who are profoundly affected. Today a new prostate cancer treatment option, ... , , ... excited to see this innovative treatment option made available for patients with ...
... South Korea , April 29 OrbusNeich today announced that ... final 12-month clinical results of the global e-HEALING Registry confirmed that the ... in this high-risk patient group. , ... The data were presented by Dr. Andres Iniguez , M.D., ...
Cached Medicine Technology:Advanced Prostate Cancer Patients Finally Have Another Option 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients 3
(Date:5/23/2013)... Parker Waichman LLP, a national law ... by defective medical devices and drugs, is proud to ... been appointed Co-Lead Counsel in the Mirena IUD multidistrict ... (Case 7:13-md-02434-CS). The Order, which was filed on May ... submit their proposal for the Court’s appointment of a ...
(Date:5/23/2013)... 2013 EnvirOasis, the leader in energy ... market is pleased to announce its new line of ... products. EnvirOasis has been a market leader in ... kits and has recently brought to market a full ... Diode) is energy efficient lighting technology which produces a ...
(Date:5/23/2013)... The sensation of itching is hardwired into the nervous ... molecule released in the spinal cord, according to a ... molecule, known as natriuretic polypeptide b (Nppb), triggers a ... this signal is experienced as an itch. Since the ... researchers concluded that a similar process probably occurs in ...
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Teen birth rates ... teens, according to a new government report. Overall, the ... by nearly one half from 1991 to 2011 -- from ... for every 1,000. From 2007 to 2011, the most ... to about 31. During that time, rates fell at ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A shortage of ... health departments across the United States to contain the ... report. The drug, isoniazid (INH), was first used ... to be the core of any first-line treatment for ... to nine months, according to the U.S. Centers for ...
Breaking Medicine News(10 mins):Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2
... Philadelphia, PA, 6 April 2010 - Attention-deficit/hyperactivity disorder (ADHD) ... affecting children and adolescents. Children with ADHD are excessively ... and in school. Problems inhibiting behavior are a common ... treated with stimulant medications, behavioral approaches or a combination ...
... ... to promote organic seed research and conserve crop genetic diversity – ultimately ensuring a ... ... The CLIF BAR Family Foundation today announced a $500,000 grant to promote organic seed ...
... more children today are surviving cancer than ever before, young ... a decade less, on average, than the general population, according ... School of Public Health. Depending on the type of ... years to more than 17 years, the scientists report in ...
... from the Department of Exercise and Sports Sciences, University ... involving both men, women and children, who were divided ... the studies are so remarkable that the Scandinavian ... publishing a special edition issue entitled "Football for Health" ...
... 65 percent in U.S., study finds , TUESDAY, April ... intentional abuse of prescription sedatives, tranquilizers and other painkilling ... research reveals. , Hospital stays from an unintentional overdose ... (such as Valium and Ativan) jumped 37 percent between ...
... ... III in Webinar Series on Opportunities for Improvement in Various Stages of the RN ... ... human capital research firm, will host a webinar titled “When Engagement Isn’t Enough: Retaining ...
Cached Medicine News:Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2Health News:CLIF BAR Family Foundation Commits $500,000 to Protect and Promote Organic Seed and Farming 2Health News:Childhood cancer survivors may face shortened lifespan, study reveals 2Health News:Childhood cancer survivors may face shortened lifespan, study reveals 3Health News:Childhood cancer survivors may face shortened lifespan, study reveals 4Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3Health News:Morehead Presents Webinar on ,“When Engagement Isn't Enough: Retaining RNs”, 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: